CD19 and neoplasm: Other toxicities of CAR T‐cell therapy may include “on target, off tumor recognition”, for example, leading to B‐cell aplasia and hypogammaglobulinemia with CD19 CAR T cells, and cytopenia due to the conditioning regimen [10].